Evaluation of SARS-CoV-2 antibody persistence and viral spread in stool: a long-term care experience before COVID-19 vaccination
- 12 July 2022
- journal article
- research article
- Published by Springer Nature in Irish Journal of Medical Science (1971 -)
- Vol. 192 (1) , 263-268
Abstract
Background Due to elderly residents, nursing homes/assisted living facilities were the most affected places in COVID-19 pandemic. Besides symptomatic patients, asymptomatic patients were detected during routine screening. Aim This study aims to determine the factors that affect antibody response and viral shedding in stool samples after natural exposure to the virus in residents and staff who recovered from COVID-19 before the vaccine was available. Methods This prospective cross-sectional study was conducted at the nation’s highest-capacity Residential and Nursing Home. Blood samples were collected between December 15, 2020 and January 15, 2021 from participating residents and staff for anti-SARS-CoV-2 antibody testing. Stool samples were obtained for SARS-CoV-2 PCR testing 2 months after COVID-19. The Social Sciences (SPSS) program version 15.0 was used for statistical analysis. The Mann–Whitney U test compared SARS‐CoV‐2 antibody concentration between two groups. Results Four hundred sixty-four (52.3%) residents and 424 (47.7%) staff participated. Entirely 259 (29.2%) participants were anti-SARS-CoV-2 IgG (+) and 255 (28.7%) were SARS-CoV-2 PCR (+). Both antibody and PCR positivity was detected in 196 (76.9%). In PCR (−) group, 63 (10.0%) participants were SARS-CoV‐2 IgG (+). Antibody titers were found highest in SARS-CoV-2 PCR (+) male residents. SARS-CoV-2 IgG titers were significantly high in SARS-CoV-2 PCR (+) and hospitalized participants regardless of age. Stool samples were obtained from 61(23.9%) participants and were found negative. Conclusion A durable SARS-CoV‐2 IgG antibody response was monitored at least 9 months after the participants were diagnosed with COVID-19. SARS-CoV-2 antibody positivity was detected 76.9% in PCR (+) and 10.0% in PCR (−) participants. Knowing the duration of detectable antibodies is an important finding for developing disease prevention and public health strategies.Keywords
Funding Information
- Dokuz Eylül Üniversitesi (2470)
This publication has 26 references indexed in Scilit:
- Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor populationJournal of Clinical Investigation, 2020
- A Review of Viral Shedding in Resolved and Convalescent COVID-19 PatientsSN Comprehensive Clinical Medicine, 2020
- Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19Signal Transduction and Targeted Therapy, 2020
- SARS-CoV-2 infection, clinical features and outcome of COVID-19 in United Kingdom nursing homesJournal of Infection, 2020
- Comparative study on virus shedding patterns in nasopharyngeal and fecal specimens of COVID-19 patientsScience China Life Sciences, 2020
- Coronavirus Disease 2019 Outcomes in French Nursing Homes That Implemented Staff Confinement With ResidentsJAMA Network Open, 2020
- COVID ‐19 in Nursing Homes: Calming the Perfect StormJournal of the American Geriatrics Society, 2020
- Characteristics of U.S. Nursing Homes with COVID ‐19 CasesJournal of the American Geriatrics Society, 2020
- Clinical and immunological assessment of asymptomatic SARS-CoV-2 infectionsNature Medicine, 2020
- Prolonged viral shedding in feces of pediatric patients with coronavirus disease 2019Journal of Microbiology, Immunology and Infection, 2020